Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues.

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

A global commission of experts has called for a radical shift in how obesity is diagnosed, with less reliance on body mass index (BMI) to define disease. The commission, published in Lancet Diabetes ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

LONDON, Dec 23 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after the drugs cost ...

The trial will enrol nearly 280 adult subjects with obesity. Credit: Hunterframe / Shutterstock. Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...

pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks. The trial will enroll approximately 280 adults who are obese (BMI ≥30 kg/m2), or adults who ...

pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks. The trial will enroll approximately 280 adults who are obese (BMI ≥30 kg/m 2), or adults who are ...